Although tumor markers, including carcinoembryonic antigen (CEA), are reliable indicators of disease progression in CRC and NSCLC [19, 20, 21], due to the non‐specific nature of these biomarkers, they cannot be used solely in clinical practice. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.